Extended Data Fig. 4: iOligo-based approaches can be used to reduce cell type-specific Cas9 gene editing in models of lung inflammation.

(a) The percentage of ICAM-2 indels in hepatocytes and (b) lung endothelial cells following treatment of Ova, iOligo / Ctrl, and sgICAM-2 / sgCtrl, *p = 0.04, **p = 0.009 one-way ANOVA, average + /- SEM.